SEARCH:   Advanced

Blood, 1 March 2007, Vol. 109, No. 5, pp. 2165-2173. Prepublished online as a Blood First Edition Paper on November 2, 2006; DOI 10.1182/blood-2006-06-028092. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2006-06-028092v1 109/5/2165    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sin, S.-H. Articles by Dittmer, D. P. Search for Related Content PubMed PubMed Citation Articles by Sin, S.-H. Articles by Dittmer, D. P. Related Collections Immunobiology Neoplasia Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling Sang-Hoon Sin1,2, Debasmita Roy1,2, Ling Wang1,2, Michelle R. Staudt1,2, Farnaz D. Fakhari1,2, Dhavalkumar D. Patel1,4, David Henry5,6, William J. Harrington, Jr7,8, Blossom A. Damania1,2, and Dirk P. Dittmer1,2 1 Department of Microbiology and Immunology, University of North Carolina at Chapel Hill; 2 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; 3 Department of Medicine, University of North Carolina at Chapel Hill; 4 Thurston Arthritis Research Center, University of North Carolina at Chapel Hill; 5 Department of Medicine, University of Pennsylvania, Philadelphia; 6 Joan Karnell Cancer Center, University of Pennsylvania, Philadelphia; 7 Sylvester Cancer Center, University of Miami, FL; 8 Department of Medicine, University of Miami, FL The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma–associated herpesvirus (KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL; (3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (4) KSHV transcription is unaffected; (5) inhibition of IL-10 signaling correlates with drug sensitivity; and (6) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307. [Abstract] [Full Text] [PDF] P. Armand, S. Gannamaneni, H. T. Kim, C. S. Cutler, V. T. Ho, J. Koreth, E. P. Alyea, A. S. LaCasce, E. D. Jacobsen, D. C. Fisher, et al. Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning J. Clin. Oncol., December 10, 2008; 26(35): 5767 - 5774. [Abstract] [Full Text] [PDF] L. Wang and B. Damania Kaposi's Sarcoma-Associated Herpesvirus Confers a Survival Advantage to Endothelial Cells Cancer Res., June 15, 2008; 68(12): 4640 - 4648. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020